Literature DB >> 28814254

Bronchiolitis Care in the Hospital.

Jennifer Orr Vincent1, Huay-Ying Lo2, Susan Wu3.   

Abstract

BACKGROUND: Viral bronchiolitis is a common cause of hospitalization in young children, but despite a variety of therapeutic options, the mainstay of treatment remains supportive care.
OBJECTIVE: To examine the most recent evidence for supportive care measures and pharmacologic options in the treatment of bronchiolitis in the hospital setting.
METHOD: MEDLINE search with expert medical librarian for publications on management and therapies for bronchiolitis.
RESULTS: Evidence does not support the use of bronchodilators, racemic epinephrine, deep suctioning, systemic corticosteroids, or antibiotics in the absence of a concomitant bacterial infection, as these treatments do not change the course of illness or shorten length of stay (LOS). Nebulized hypertonic saline is not routinely recommended, though it may provide some benefit for patients with anticipated prolonged LOS. Continuous pulse oximetry should not be routinely used in stable patients as it may be associated with longer LOS. Supplemental oxygen should be used to maintain oxyhemoglobin concentrations ≥90%, a level lower than what many clinicians may have used previously. Current evidence suggests high-flow nasal cannula may reduce intubation rate, but its effect on LOS is unclear. Intravenous or nasogastric tube hydration should be used when oral hydration is not sufficient.
CONCLUSION: Overall, bronchiolitis remains a self-limited disease whose mainstay of therapy is supportive care. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Bronchiolitis; high-flow nasal cannula (HFNC); hypertonic saline (HTS); length-of-stay (LOS); oxygen; respiratoryzzm321990syncytial virus (RSV)

Mesh:

Year:  2017        PMID: 28814254     DOI: 10.2174/1574887112666170816152832

Source DB:  PubMed          Journal:  Rev Recent Clin Trials        ISSN: 1574-8871


  2 in total

1.  TGF-β1 Suppresses the Type I IFN Response and Induces Mitochondrial Dysfunction in Alveolar Macrophages.

Authors:  Jocelyn R Grunwell; Samantha M Yeligar; Susan Stephenson; Xiao Du Ping; Theresa W Gauthier; Anne M Fitzpatrick; Lou Ann S Brown
Journal:  J Immunol       Date:  2018-02-02       Impact factor: 5.422

2.  Typology of morbidity diagnosed in a pediatric department of a secondary care center (Msaken, Sousse, Tunisia).

Authors:  Chokri Zoghlami; Imen Horrigue; Mohamed Khelil; Sarra Nouira; Dhekra Chebil; Taoufik Jrad; Ahmed Ben Abdelaziz
Journal:  Tunis Med       Date:  2021-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.